Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyruvate dehydrogenase (PDH) is a key enzyme that catalyzes the conversion of pyruvate, the end product of glycolysis, into acetyl-CoA, which then enters the tricarboxylic acid (TCA) cycle. This reaction also produces carbon dioxide (CO₂) and reduces NAD⁺ to NADH. The PDH reaction serves as a critical link between glycolysis and aerobic respiration. The PDH is not a single protein but is part of a large multi-enzyme complex called the pyruvate dehydrogenase complex (PDC). PDHC acts as a gatekeeper for carbohydrate entry into mitochondrial metabolism—its activity determines whether glucose-derived carbons enter oxidative phosphorylation or alternative pathways like lactate production under hypoxia or in cancer cells. Dysregulation has been implicated in metabolic diseases, and mutations can cause neurological disorders due to impaired energy metabolism in neurons.
Inhibition of Pyruvate Dehydrogenase Kinase (PDK)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyruvate Dehydrogenase (PDH).